



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On

5/9/03

TOWNSEND and TOWNSEND and CREW LLP

By:

Jonathan K. Handin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Scarborough et al.

Application No.: 09/920,325

Filed: August 2, 2001

For: PLATELET ADP RECEPTOR
INHIBITORS

Examiner: Bruck Kifle

Art Unit: 1624

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 12, 2003, please amend the above-identified application as follows.

This amendment has been prepared under the newly revised format set forth by the USPTO in the Office of Patent Legal Administration Pre-OG Notice of January 31, 2003. It is Applicants understanding that by following the provisions of the new format, the provisions under 37 CFR § 1.121(a), (b), (c) and (d) are waived for amendments to the claims, specification and drawings.

PATENT
Attorney Docket No.: 021390-002040US
Client Ref. No.: MPI00-596P3RNCP1

#11/A
5/24/03
C. style

TECH CENTER 1600/2900

MAY 13 2003

RECEIVED